<DOC>
	<DOCNO>NCT00003068</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill tumor cell . PURPOSE : Phase II trial study effectiveness high-dose mitoxantrone , thiotepa , cyclophosphamide plus autologous peripheral stem cell transplantation amifostine treat patient primary , locally advanced , stage IV breast cancer .</brief_summary>
	<brief_title>High-Dose Chemotherapy Autologous Blood Cell Transplantation Treating Patients With Primary , Locally Advanced , Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dos mitoxantrone cyclophosphamide administer combination thiotepa , autologous blood cell , amifostine patient primary , locally advanced , metastatic breast cancer , determine whether amifostine , cytoprotection agent , allow administration high dose chemotherapy . II . Determine dose limit toxicity regimen administer patient primary , locally advanced , metastatic breast cancer . III . Evaluate toxicity amifostine , cytoprotection agent , administer multiple dos breast cancer patient receive high dose chemotherapy autologous blood cell transplantation . IV . Document antitumor efficacy regimen versus freedom recurrence overall survival autologous blood cell transplantation . V. Assess contribution disease , treatment , personal characteristic affect quality life patient patient 's primary caregiver . OUTLINE : This dose escalation study . Autologous blood cell collect completion neoadjuvant/induction chemotherapy ( salvage mastectomy , indicate ) . Patients receive IV amifostine , mitoxantrone , thiotepa day -7 . On day -6 , patient receive IV amifostine , thiotepa , cyclophosphamide treatment . On day -5 , -4 , -3 , IV amifostine cyclophosphamide administer participant . Following high dose chemotherapy treatment , patient rest day -2 -1 . On day 0 , patient undergo autologous blood cell transplantation . Cohorts 3 patient receive escalate dos mitoxantrone cyclophosphamide . If 1 3 patient give dose level experience dose limit toxicity ( DLT ) , additional 3 patient treat dose . If least 3 6 patient experience DLT give dose level , maximum tolerate dose previous dose level . Patients follow day 100 , every 6 month 2 year , annually death . PROJECTED ACCRUAL : A total 30 patient accrue .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primary , locally advanced ( least 10 axillary lymph node metastases T4 N2 , M0 disease ) , stage IV breast cancer Patients least 10 axillary node metastasis distant metastasis receive adjuvant chemotherapy doxorubicin contain regimen Patients T4 N2 , M0 disease prior chemotherapy receive neoadjuvant induction chemotherapy prior salvage mastectomy ( patient must show partial remission base tumor palpation ) Patients stage IV breast cancer receive induction chemotherapy doxorubicin ( unless relapse less 1 year follow therapy metastatic disease progression observe great 300 mg/m2 previously take , may receive induction chemotherapy paclitaxel regimen ) Stage IV cancer patient must least partial remission follow induction chemotherapy Stage IV cancer patient minimal metastatic disease ( chest wall recurrence bone ) ; patient extensive and/or visceral metastasis must near complete remission follow induction chemotherapy PATIENT CHARACTERISTICS : Age : 16 70 Performance Status : SWOG 01 Karnofsky 80100 % Life Expectancy : At least 2 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 time upper limit normal ( ULN ) ( unless tumor relate ) SGOT SGPT less 2.0 time ULN ( unless tumor relate ) Alkaline phosphatase less 2.0 time ULN ( unless tumor relate ) Renal : Creatinine within institutional normal limit Cardiovascular : Cardiac ventricular ejection fraction ( MUGA ) echocardiogram within normal limit prior high dose chemotherapy No uncontrolled severe cardiovascular disease No myocardial infarction within 6 month No congestive heart failure No symptomatic angina No life threaten arrhythmias No hypertension Pulmonary : Pulmonary function test great 75 % predict normal Room air arterial blood gas within normal limit Other : Not HIV positive Not hepatitis B surface antigen positive Not hepatitis C antibody positive No serious organ dysfunction ( unless cause breast cancer ) No active bacterial , viral , fungal infection No active peptic ulcer No uncontrolled diabetes Not pregnant Effective contraceptive method must use study Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
</DOC>